4-氰甲基苯硼酸 | 91983-26-5

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰甲基苯硼酸
• 中文别名: 4-(氰基甲基)苯硼酸
• 英文名称: 4-(cyanomethyl)phenylboronic acid
• 英文别名: 4-(cyanomethyl)benzeneboronic acid；[4-(cyanomethyl)phenyl]boronic acid
• CAS: 91983-26-5
• 化学式: C₈H₈BNO₂
• mdl: MFCD01632200
• 分子量: 160.968
• InChiKey: YKVMTTIYBSVPEQ-UHFFFAOYSA-N

物化性质

• 熔点：
  138-142°C
• 沸点：
  375.7±44.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  按规定使用和贮存的话，这些物质是不会分解的，应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.11
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  64.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/22,R36/37/38
• 危险品运输编号：
  3439
• 海关编码：
  2931900090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352+P312+P362+P364,P304+P340+P312,P305+P351+P338+P337+P313,P501
• 危险性描述：
  H302+H312+H332,H315,H319
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Cyanomethylphenylboronic acid
Synonyms: (4-Boronophenyl)acetonitrile

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Cyanomethylphenylboronic acid
CAS number: 91983-26-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8BNO2
Molecular weight: 161.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氰甲基苯硼酸 在 N,N-二异丙基乙胺 作用下， 以 水 、 乙腈 为溶剂， 反应 12.0h， 以91%的产率得到对羟基苯乙腈
  参考文献：
  名称：

  通过壁面工程轻松构建烯烃连接的共价有机框架以增强光催化有机转化

  摘要：

  探索基于完全共轭共价有机骨架（COF）的光催化剂由于其优异的稳定性、出色的半导体性能和令人着迷的特性而成为有价值的研究。然而，烯烃连接的 COF 基光催化剂的设计和构建仍处于起步阶段。在此，设计并合成了三种具有高结晶度和卓越稳定性的烯烃连接二维 COF（F-TBT-COF、TBT-COF 和 MeO-TBT-COF） 。芳基醛单体（F-TBT、H-TBT 和 MeO-TBT）和 2,4,6-三甲基-1,3,5-三嗪 (TMT) 的 Knoevenagel 缩合。值得注意的是，这些 COF 的孔壁表面与单个原子或单元对接，以诱导不同的感应和共轭效应。然后这些效应传递到 COF 的主干，从而可以通过壁面工程来调节 COF 的吸收范围、带隙和电荷转移效率。具有表面甲氧基位点的 MeO-TBT-COF 在可见光驱动的吲哚衍生物 C-3 硫氰化反应和芳基硼酸向苯酚的需氧转化中表现出最高的光催化活性和

  DOI：

  10.1039/d1ta09684b
• 作为产物：
  描述：

  4-氰甲基苯硼酸频哪醇酯 在 sodium periodate 、 ammonium acetate 作用下， 以 水 、 丙酮 为溶剂， 反应 2.0h， 以100%的产率得到4-氰甲基苯硼酸
  参考文献：
  名称：

  Sulfonamide derivatives

  摘要：

  本发明提供了一些磺胺衍生物，可用于增强患者的谷氨酸受体功能，因此可用于治疗多种疾病，如精神疾病和神经系统疾病。

  公开号：

  US20030225266A1
• 作为试剂：
  描述：

  5-[2-(4-bromo-2-chloro-phenyl)-1-hydroxy-1-trifluoromethyl-propyl]-1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one 、 Dicaesio carbonate 、 4-氰甲基苯硼酸 、 水 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 4-氰甲基苯硼酸 作用下， 以 1,4-二氧六环 、 甲酸 为溶剂， 反应 0.33h， 以HPLC (C18-column, solvent gradient 30-98%) to give the title compound (27 mg)的产率得到{3'-chloro-4'-[2-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-3,3,3-trifluoro-2-hydroxy-1-methyl-propyl]-biphenyl-4-yl}-acetonitrile
  参考文献：
  名称：

  2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds

  摘要：

  本发明涉及公式I的化合物，其中R1a到R1e，R2，R3和R5如描述和要求中所定义，R4表示双环杂芳基团或氰基苯基团，以及其药学上可接受的盐。这些化合物是糖皮质激素受体拮抗剂，可用于治疗和/或预防糖尿病、脂质代谢异常、肥胖症、高血压、心血管疾病、肾上腺失衡或抑郁症等疾病。

  公开号：

  US08450313B2

文献信息

• CHEMICAL COMPOUNDS
  申请人：Deng Jianghe

  公开号：US20090143372A1

  公开（公告）日：2009-06-04

  The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型吲哚羧酰胺衍生物。具体而言，该发明涉及符合以下式I的化合物： 其中R1、R2、R3、U和V如下定义，并且其药学上可接受的盐。该发明的化合物是IKK2的抑制剂，可用于治疗与不当IKK2（也称为IKKβ）活性相关的疾病，如类风湿性关节炎、哮喘和慢性阻塞性肺病（COPD）。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制IKK2活性和治疗相关疾病的方法。
• New Steroidal 4-Aminoquinolines Antagonize Botulinum Neurotoxin Serotype A in Mouse Embryonic Stem Cell Derived Motor Neurons in Postintoxication Model
  作者：Jelena Konstantinović、Erkan Kiris、Krishna P. Kota、Johanny Kugelman-Tonos、Milica Videnović、Lisa H. Cazares、Nataša Terzić Jovanović、Tatjana Ž. Verbić、Boban Andjelković、Allen J. Duplantier、Sina Bavari、Bogdan A. Šolaja

  DOI：10.1021/acs.jmedchem.7b01710

  日期：2018.2.22

  The synthesis and inhibitory potencies against botulinum neurotoxin serotype A light chain (BoNT/A LC) using in vitro HPLC based enzymatic assay for various steroidal, benzothiophene, thiophene, and adamantane 4-aminoquinoline derivatives are described. In addition, the compounds were evaluated for the activity against BoNT/A holotoxin in mouse embryonic stem cell derived motor neurons. Steroidal derivative

  描述了使用基于体外HPLC的酶法测定各种甾体，苯并噻吩，噻吩和金刚烷4-氨基喹啉衍生物对A型肉毒杆菌神经毒素轻链（BoNT / A LC）的合成和抑制能力。另外，评估了化合物在小鼠胚胎干细胞衍生的运动神经元中对BoNT / A全毒素的活性。甚至在中毒后30分钟给药，类固醇衍生物16也显示出显着的保护作用（高达89％的未裂解SNAP-25）。这似乎是LC抑制剂在暴露后模型中拮抗小鼠胚胎干细胞衍生的运动神经元（mES-MNs）中BoNT中毒的第一个例子。口服16 高达600 mg / kg，qd的小鼠具有良好的耐受性，尽管在该剂量下未达到足够的未结合药物水平，但体外ADMET的良好结果有力地支持了该系列的进一步工作。
• Monofluoroalkyl derivatives
  申请人：Eli Lilly and Company

  公开号：US07034045B1

  公开（公告）日：2006-04-25

  The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

  本发明提供了一些单氟代烷基衍生物，这些衍生物可用于增强哺乳动物中的谷氨酸受体功能，因此可用于治疗各种疾病，如精神和神经障碍。
• TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS
  申请人：Incyte Corporation

  公开号：US20140121198A1

  公开（公告）日：2014-05-01

  The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

  本发明提供了三环融合噻吩衍生物，以及它们的组合物和使用方法，这些衍生物调节Janus激酶（JAK）的活性，并且在治疗与JAK活性相关的疾病方面具有用处，例如炎症性疾病、自身免疫性疾病、癌症和其他疾病。
• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION COMME MÉDICAMENTS THÉRAPEUTIQUES
  申请人：DONG-A SOCIO HOLDINGS CO LTD

  公开号：WO2017039331A1

  公开（公告）日：2017-03-09

  The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

  本发明提供了一种杂环化合物、其立体异构体、对映异构体或药用可接受的盐，这些化合物能够调节Mer受体酪氨酸激酶（MERTK）的活性。本发明还提供了这些化合物的药物组合物、制备所述化合物的方法以及将这些化合物用作药物的应用。本发明针对的是具有显著活性的MERTK抑制性化合物，因此具有在癌症和任何与MERTK调控失调相关的疾病中进行药物干预的卓越潜力。